Internal Medicine, Critical Care Medicine · Riverview, MI
NPI
1649240177
Since 2006
Specialty
Internal Medicine, Critical Care Medicine
Code 207RC0200X
Group practices
6
Medicare group memberships
Hospitals
5
Hospital affiliations
18025 Fort Street
Riverview, MI, 48193
Phone (734) 283-5555
Groups this clinician bills Medicare through
Medicare paid, 2024
$210K
2,434 services
Medicare patients, 2024
724
Average age 71
Drug cost, 2024
$1.8M
4,173 prescriptions
Company payments, 2025
$1,814
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Asker Asmi was code 99214 (office e&m - established), 771 times for 492 patients. In total Asker Asmi billed 2,434 services in 25 codes, and Medicare paid $210K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-09-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 771 | 492 | $96.95 | $75K |
| 99213 Office E&M - Established | Office | 242 | 208 | $68.95 | $17K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 179 | 47 | $48.11 | $8,611 |
| 99457 E&M - Miscellaneous | Office | 167 | 76 | $37.54 | $6,269 |
| 94729 Pulmonary Function Testing | Office | 164 | 158 | $43.08 | $7,065 |
| 99204 Office E&M - New | Office | 120 | 119 | $124.54 | $15K |
| 94010 Pulmonary Function Testing | Office | 111 | 107 | $21.05 | $2,337 |
| 94618 Pulmonary Function Testing | Office | 108 | 102 | $26.53 | $2,865 |
| 94727 Pulmonary Function Testing | Office | 101 | 97 | $34.20 | $3,455 |
| 99215 Office E&M - Established | Office | 89 | 75 | $130.70 | $12K |
| 94060 Pulmonary Function Testing | Office | 69 | 64 | $30.04 | $2,073 |
| 94726 Pulmonary Function Testing | Office | 62 | 60 | $40.86 | $2,534 |
| 95810 Sleep Study | Office | 53 | 49 | $482.26 | $26K |
| 99205 Office E&M - New | Office | 41 | 41 | $148.53 | $6,090 |
| 95811 Sleep Study | Office | 40 | 40 | $483.62 | $19K |
By year: 2022 $324K for 3,577 services; 2023 $275K for 2,947 services; 2024 $210K for 2,434 services.
Medicare prescription drug claims, 2024
In 2024, the drug Asker Asmi prescribed most often to Medicare patients was Albuterol Sulfate Hfa (Albuterol Sulfate), with 447 prescriptions and refills. In total Asker Asmi wrote 4,173 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | 447 | 544 | 138 | $13K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 389 | 579 | 90 | $353K |
| Advair Hfa Fluticasone Propion/Salmeterol | 373 | 461 | 111 | $183K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 314 | 408 | 92 | $53K |
| Ipratropium Bromide Generic | 256 | 719 | 145 | $9,765 |
| Spiriva Respimat Tiotropium Bromide | 253 | 318 | 61 | $158K |
| Montelukast Sodium Generic | 209 | 518 | 56 | $3,569 |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 138 | 170 | 38 | $33K |
| Dulera Mometasone/Formoterol | 135 | 155 | 30 | $52K |
| Symbicort Budesonide/Formoterol Fumarate | 134 | 170 | 32 | $39K |
| Incruse Ellipta Umeclidinium Bromide | 113 | 145 | 33 | $46K |
| Prednisone Generic | 105 | 111 | 75 | $383 |
| Eszopiclone Generic | 100 | 104 | 24 | $1,147 |
| Doxepin Hcl Generic | 99 | 128 | 35 | $1,090 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 98 | 108 | 22 | $66K |
Brand drugs: 2,253 claims; generic drugs: 1,920 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Asker Asmi $1,814 ($1,814 in general payments such as food, travel and fees) from 21 companies. The largest payer was GlaxoSmithKline, LLC. with $355.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 23 | $355 |
| AstraZeneca Pharmaceuticals LP AZN | 19 | $353 |
| Insmed, Inc. INSM | 10 | $229 |
| Harmony Biosciences LLC HRMY | 7 | $186 |
| Grifols USA, LLC | 4 | $122 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $89.28 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $67.61 |
| Pulmonx Corporation LUNG | 3 | $64.45 |
| Genzyme Corporation SNY | 3 | $47.94 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $44.13 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.